Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Why FDA optimized for flexibility with COVID-19 vaccine booster choice

By Brian Buntz | October 21, 2021

FDA logoEarly data seem to suggest that mRNA vaccine boosters are more effective than additional doses of the adenovirus-vector COVID-19 vaccines from AstraZeneca and Johnson & Johnson.

But scientists don’t currently have “any real clinical effectiveness data on this question,” said Dr. Janet Woodcock, acting FDA commissioner.

To date, vaccine developers have heavily relied on antibody response data to measure the immune response additional vaccine doses offer.

“We really don’t know the connection between [antibody response data] and actually how well protected somebody is,” Woodcock said.

Further complicating matters is the fact that such antibody levels are a measure of a short-term immune response, said Dr. Peter Marks, director of the Center for Biologics Evaluation and Research (CBER) at FDA.

“That’s not to discourage people from getting these boosters,” Marks said.

But scientists have comparatively little data on T cell immunity to COVID-19, which is involved in longer-term immunity. “And it is indeed possible that something that does not give you as high of a level of the antibodies upfront may protect you for a longer period of time, or more robustly later on,” Marks said.

Because of the lack of data, FDA has decided that a non-committal approach would work best about recommending combinations of boosters. Any combination of boosters may be reasonable for most people.

Individuals who had a bad reaction to prior COVID-19 vaccination, however, should research with their physician the prospect of receiving a different type of booster, Woodcock said.

In the future, it is possible that authorities treat COVID-19 boosters as largely interchangeable, Marks hinted. “Most people don’t know what brand flu vaccine they received and although they’re somewhat more standardized [than COVID-19 vaccines],” Marks said.

A flexible strategy for providing COVID-19 boosters could facilitate vaccination — especially in “institutions where it might be hard to go patient by patient and figure out what they received six or eight months ago,” Marks said.


Filed Under: Infectious Disease
Tagged With: covid-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, FDA, Janssen, Johnson & Johnson, Moderna, Pfizer
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

JYNNEOS vaccine
Jynneos vaccine: The best weapon against monkeypox?
Axcella
Axcella touts positive results from Phase 2a long COVID study
monkeypox
3 critical monkeypox vaccine questions 
Moderna in the Drug Discovery & Development Pharma 50
Moderna inks deal with US for up to 300M omicron boosters

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50